ELVN- Enliven Therapeutics, Inc.

Name: Enliven Therapeutics, Inc. Insider Trading Data
Creator: U.S. Securities and Exchange Commission
License: https://www.sec.gov/privacy#accessibility

Enliven Therapeutics, Inc. (ELVN) has 10 insiders with recent SEC Form 4 filings, including 0 buys and 18 sells. ELVN is classified in the Biotechnology industry within the Health Care sector.

Insider Ownership

Role	Insider	Shares	Value	30d
10%	Orbimed Advisors LLC	7.39M	$441.12M	-
CEO	Kintz Samuel	890.4K	$53.16M	-
CEO	Fair Richard A.	875.0K	$52.24M	-
Other	Lyssikatos Joseph P	740.2K	$44.19M	-
COO	Patel Anish	215.3K	$12.85M	-

Activity

Buys and sells only

Transactions

10 filings · page 2

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Jan 9, 2026	Heyman Richard A.74	Director	Sell	13,920	$25.02	$348,280.95	-14.8%	+75.3%	-
Jan 9, 2026	Lyssikatos Joseph P49	Chief Scientific Officer	Sell	132,500	$26.23	$3,476,013.95	-3.8%	+75.3%	-
Dec 19, 2025	Lyssikatos Joseph P49	Chief Scientific Officer	Sell	5,000	$16.84	$84,206.00	-0.6%	+78.1%	-
Dec 8, 2025	Patel Anish53	Chief Operating Officer	Sell	6,663	$21.02	$140,072.86	-1.2%	+45.1%	-
Nov 19, 2025	Lyssikatos Joseph P49	Chief Scientific Officer	Sell	12,500	$22.33	$279,154.78	-0.7%	+18.2%	-
Nov 17, 2025	Kintz Samuel50	President And CEO	Sell	12,500	$21.82	$272,738.75	-1.4%	+20.1%	-
Nov 7, 2025	Patel Anish53	Chief Operating Officer	Sell	6,667	$17.40	$116,034.16	-1.2%	+53.1%	-
Oct 20, 2025	Lyssikatos Joseph P49	Chief Scientific Officer	Sell	12,500	$22.08	$276,025.00	-1.3%	+22.3%	-
Oct 17, 2025	Kintz Samuel50	President And CEO	Sell	12,500	$21.33	$266,653.75	-1.4%	+17.6%	-
Oct 7, 2025	Patel Anish53	Chief Operating Officer	Sell	6,667	$20.10	$133,992.70	-2.4%	-24.4%	-

← PrevPage 2Next →

Insider	Role	Shares	Value	Buys	Sells

Date	Ticker	Insider	Role	Type	Shares	Price	Value	Chg%	SEC